Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzymes are overexpressed during inflammation and multistage tumor progression in many neoplastic disorders including lung, breast and pancreatic cancers. Here we report that the tumor suppressor phosphatase and tensin homolog (PTEN) is oxidized and inactivated during arachidonic acid (AA) metabolism in pancreatic cancer cell lines expressing COX-2 or 5-LOX. Oxidation of PTEN decreases its phosphatase activity, favoring increased phosphatidylinositol 3,4,5-triphosphate production, activation of Akt and phosphorylation of downstream Akt targets including GSK-3b and S6K. These effects are recapitulated with pancreatic phospholipase A 2 , which hydrolyses the release of membrane-bound AA. Interference with PTEN's physiological antagonism of signals from growth factors, insulin and oncogenes may confer risk for hypertrophic or neoplastic diseases associated with chronic inflammation or unwarranted oxidative metabolism of essential fatty acids.
Introduction
Akt is a serine-threonine kinase involved in metabolism, proliferation, motility and survival (Fresno Vara et al., 2004) . Regulation of Akt requires the participation of several different proteins. Following stimulation by growth factors or other mediators, phosphoinositide 3-kinase (PI3K) generates a lipid product called phosphatidylinositol 3,4,5-triphosphate (PIP 3 ) (Cantley and Neel, 1999) . Generation of PIP 3 recruits Akt to the plasma membrane through a pleckstrin homology (PH) domain. At the membrane, Akt is fully activated after phosphorylation by phosphoinositide-dependent kinase-1 (PDK1) and PDK2 at residues Thr308 and Ser473, respectively (Chan et al., 1999) . Subsequently, Akt can phosphorylate many downstream proteins and thereby positively and negatively regulate diverse signaling pathways.
Akt signaling is restrained by PTEN (phosphatase and tensin homolog deleted on chromosome 10), a phosphatase and tumor suppressor that dephosporylates PIP 3 to PIP 2 (Leslie and Downes, 2002) . By reducing the levels of PIP 3, PTEN inhibits the recruitment of Akt to the plasma membrane and prevents its activation. PTEN function is regulated by post-translational modification, cellular localization and redox modulation at the active-site cysteine (Lee et al., 2002; Yu et al., 2005; Gericke et al., 2006) .
Arachidonic acid (AA) is an essential fatty acid involved in the inflammatory response. AA is metabolized by cyclooxygenase (COX) and lipoxygenase (LOX) enzymes into prostaglandins (PG) and leukotrienes (LT), respectively. There is increasing support to show that essential fatty acids stimulate cell growth; however, the mechanism is not fully understood (Marks et al., 2000) . Recent reports indicate that AA causes an increase in phosphorylation of Akt, although the means for this is unclear. Some reports indicate that the activation of Akt is PI3K dependent (Hii et al., 2001; Hughes-Fulford et al., 2006; Wildroudt and Freeman, 2006) and others report it is PI3K independent (Gorin et al., 2001) . Some reports indicate that AA metabolism is necessary (Hii et al., 2001; Li and Malik, 2005; Hughes-Fulford et al., 2006) and others report that AA metabolism is not a factor (Gorin et al., 2001) .
Mounting evidence suggests that both 5-LOX and COX-2 influence the progression of several human cancers (Aggarwal et al., 2006) , including pancreatic cancer (Ding et al., 2001) . Using BxPC3, AsPC1 and PL-45 pancreatic cancer cells, which have COX-2 and/or 5-LOX expression, we report that AA metabolism leads to an increase in Akt phosphorylation. We show that the mechanism responsible for this is oxidation and inactivation of PTEN tumor suppressor. Oxidation of PTEN by AA metabolism decreases its activity, elevates PIP 3 levels and increases signaling through Akt and its downstream targets. These effects are recapitulated with pancreatic phospholipase A 2 (PLA 2 ), an enzyme that catalyses the release of AA from membranes in pancreatic ducts. Disruption of PTEN and other tumor suppressors by labile mediators may contribute to the etiology of cancers associated with chronic inflammation or overexpression of COX and LOX (Wagner et al., 2006) .
Results
Pancreatic cancer cells coexpress COX-2 and 5-LOX enzymes Abnormal expression of both COX and LOX has been reported in pancreatic cancer (Xiong, 2004) . To study the effects of AA metabolism on cell signaling, four pancreatic cancer cell lines (BxPC3, AsPC1, Panc-1 and PL-45) were chosen for their differing expression of COX and LOX enzymes ( Figure 1a ). All four cell lines expressed PTEN. The Panc-1 cells had no COX-2 and little COX-1 or 5-LOX expression, thus serving as a control cell line with diminutive AA metabolism. The AsPC1 cells have COX-1 and 5-LOX. PL-45 have 5-LOX and modest COX-1. BxPC3 cells have COX-2 and 5-LOX with modest COX-1 expression. COX-2 is the main source of PGs in these cells. For instance, BxPC3 cells treated 30 min with 60 mM AA secreted 14.471.9 ng PGE 2 /ml, 0.7 ng PGD 2 /ml and 0.870.02 ng leukotriene B 4 (LTB 4 )/ml. These values were B5-fold above the control levels 2.971.0 ng PGE 2 /ml, 0.1 ng PGD 2 /ml and 0.1670.04 ng/LTB 4 /ml secreted by BxPC3 cells in medium without AA (po0.05). By contrast, AsPC1 cells, which express COX-1 but not COX-2, secreted 3.071.7 ng/ml PGE 2 and 2.671.2 ng/ml (P>0.05) when treated with 60 mM AA or vehicle, respectively (data not shown). LTB 4 levels were similar to BxPC3 cells. Oxidation of PTEN by AA metabolism TM Covey et al not respond to AA treatment with an increase in Akt phosphorylation; these cells have little potential to metabolize AA (Figure 1a ). The BxPC3, AsPC1 and PL-45 cells treated with AA had a rapid increase in phospho-(S473)Akt that occurred within 5 min and lasted up to 2 h (Figure 1c ). This effect occurred with doses as low as 10-20 mM AA (Figure 1b) . Additionally, AA treatment increased signaling to proteins with a K/ RxK/RxxS/T epitope, the consensus phosphorylation site for AKT substrates (Figure 1c and d) . 
ROS scavengers attenuate the phosphorylation of Akt
During oxidative metabolism of AA by COX-2 and LOX, there is an increase in reactive oxygen species (ROS) and reactive oxygen lipid species (ROLS) (Giardina and Inan, 1998) . To determine whether these species, rather than autocoid metabolites, were having an effect on Akt activity, cells were treated with ROS scavengers Tiron and N-mercaptopropionylglycine (MPG) before AA treatment. Akt (S473) phosphorylation was reduced 45% in samples treated with tiron or 85% in samples treated with tiron and MPG before AA treatment compared with AA treatment alone ( Figure 2c , lane 2 versus 4, 6).
PTEN activity is decreased upon AA treatment
The PTEN active site contains a nucleophilic cysteine residue susceptible to oxidation and, perhaps, alkylation because of its low pK a . To determine whether or not PTEN activity was affected during oxidative metabolism of AA, PIP 3 levels were measured. BxPC3 cells and AsPC1 cells treated with vehicle had little to no PIP 3 , however, stimulation with AA increased PIP 3 (Figure 3c ). To confirm that increased activation of PI3K was not responsible for the increase in PIP 3 levels, cells were treated with small interfering RNA (siRNA) . Additionally, tyrosine phosphorylated PI3K docking sites (i.e. phospho-Y-XXM) showed no increase following AA treatment, which further supports the conclusion that PI3K is not activated by AA (data not shown). Therefore, AA stimulates Akt indirectly through PTEN inactivation rather than PI3K activation.
PTEN is oxidized during AA metabolism by COX-2 and 5-LOX PTEN, like the other members of the protein tyrosine phosphatase (PTP) family, has a signature motif of HCXXXXXR at the active site (Cho et al., 2004) . This sequence lowers the pK a of the cysteine and facilitates its (Figure 3d, lane 3) . The active-site cysteine of PTPs can be oxidized to several species by various ROS (Tonks, 2005) . To address whether PTEN was oxidized to a species other than Cys124-Cys71 disulfide during oxidative metabolism of AA, we followed a protocol that allows oxidized cysteine residues to be selectively tagged with N-ethylmaleimide (NEM)-biotin and the oxidized proteins can be isolated by immunoprecipitation with neutravidin beads (Kwon et al., 2004) . We found increased oxidized PTEN in the neutravidin immunoprecipitation from cells treated with AA compared to control (Figure 3e , lane 1 versus 2). This demonstrates that PTEN was oxidized following AA treatment and that the species formed was capable of being reduced by dithiothreitol (DTT). Furthermore, pretreatment with COX-2 and 5-LOX inhibitors or Tiron and MPG ROS scavenger prevented formation of the oxidized PTEN species, consistent with our hypothesis that AA metabolism causes oxidation of PTEN (Figure 3f ).
Activation of Akt by AA metabolism increases downstream signaling
Pancreatic cancer cells treated with AA also exhibited changes in phosphorylation of GSK-3b, FAK, FoxO1 and S6K, proteins that lie downstream of Akt (Figure 4a) . Proteins above Akt in the signaling pathway such as PDK1 did not have a change in phosphorylation (Figure 4a ). Cells treated with AA have an increased motility compared to control cells (Figure 4b , c versus e), consistent with Akt inhibiting GSK-3b activity, activating FAK and promoting tumor invasiveness Bianchi et al., 2005) .
PLA 2 recapitulates stimulation of Akt and oxidation of PTEN Pancreatic PLA 2 catalyses the release of free AA from cell membranes, as well as chylomicrons in the gut. Cells treated with PLA 2 exhibited increased Akt phosphorylation over time (Figure 5a and b) . The activation of Akt was prolonged 2 h with PLA 2 compared with exogenous AA treatment, perhaps owing to a more continuous exposure to AA. Further, the mechanism of Akt activation by pancreatic PLA 2 was also due to PTEN oxidation (Figure 5c ).
Discussion
We conclude that cellular metabolism of the essential fatty acid AA causes the corresponding oxidation and inactivation of PTEN tumor suppressor, accompanied by activation of Akt. Akt can propagate oncogenic signaling via target proteins with a consensus sequence for Ser/Thr phosphorylation, such as GSK-3b. When GSK-3b is negatively regulated by phosphorylation at Ser9 (Cross et al., 1995) , it enhances cell migration via dephosphorylation of focal adhesion kinase (FAK) at Ser722 Bianchi et al., 2005) consistent with our results. Inactivation of PTEN also propagates signaling to proteins further downstream, like S6K on the Akt -Tsc1/2 -mTor -S6K axis. S6K is a Ser/Thr kinase involved in protein translation and cell growth. Excessive, dysregulated protein translation is important in several cancers and premalignant conditions (Watkins and Norbury, 2002; Brugarolas and Kaelin, 2004) .
Hyperactivation of Akt proto-oncogene plays a key role in the proliferation and survival of subsets of pancreatic epithelial cancer cells (Mimeault et al., 2005) . Pancreas-restricted knockout of PTEN leads to ductal malignancy in mice (Stanger et al., 2005) , and the expression of PTEN is significantly decreased in a number of pancreatic cancer cells and tumor tissues (Asano et al., 2004) . These investigations show that PTEN downregulation is relevant to multistage tumor progression in the pancreas. BxPC3, AsPC1 and PL-45 cells do not display constitutive Akt phosphorylation nor do they have downregulated PTEN expression. However, oxidation and inactivation of PTEN protein during AA metabolism in these cells has consequences comparable to decreased PTEN expression (Figure 3) . The epistatic interaction between PTEN:COX-2 and PTEN:5-LOX may represent a novel inactivation process relevant to the etiology of pancreatic and other cancers. In other words, inactivation of PTEN tumor suppressor at the protein level may represent a non-classical 'hit' to PTEN tumor suppressor. Such novel inactivation mechanisms may partly reconcile Knudson's two hit model with certain haploinsufficient tumor suppressors. Haploinsufficiency occurs when loss of one allele results in an abnormal phenotype. PTEN is a haploinsufficient tumor suppressor (Kwabi-Addo et al., 2001; Trotman et al., 2003) . In situations where there is genetic or epigenetic loss of one allele of PTEN, inactivation of PTEN at the protein level could have functional consequences analogous to a second hit (biallelic inactivation). Biallelic inactivation of PTEN occurs in advanced cancers or metastases (Chu and Tarnawski, 2004) . Thus, cancers associated with the loss of a PTEN allele and increased COX-2/ LOX expression may have a particularly aggressive phenotype.
Oxidation of PTEN by ROS/H 2 O 2 has been reported in macrophages stimulated with lipopolysaccharide and phorbol ester (Leslie et al., 2003) , in HEK293 cells stimulated with insulin (Kwon et al., 2004) , in HeLa cells stimulated with epidermal growth factor (EGF) (Kwon et al., 2004) , and in fibroblasts stimulated with platelet-derived growth factor (PDGF) (Seo et al., 2005) . Despite the limited degree of PTEN oxidation in these studies, there are ample functional consequences. PTEN oxidation B2-3-fold may involve a substantial portion of the active fraction of PTEN in a cell. We have shown here that metabolism of AA oxidizes and inactivates a significant fraction of PTEN (4-5 times that of control). This is the first report that we are aware of showing that oxidation and inactivation of PTEN accompanies cellular metabolism of essential fatty acids.
PLA 2 enzymes catalyse the hydrolysis of the sn-2 fatty acyl chain of phospholipid substrates to yield fatty acids and lysophospholipids. Their enzymatic activity is a rate-limiting step in the formation of free AA for metabolism by COX and LOX enzymes. Overexpression of secreted and cytosolic PLA 2 has been reported in several tumor types including pancreatic cancers (Nevalainen et al., 1985; Yamashita et al., 1994) . Certain types of PLA 2 are also increased and contribute to morphological changes that occur during chronic pancreatitis (Vinokurova et al., 2001) . We have shown that PLA 2 treatment can recapitulate and prolong the effects of AA on Akt activation and PTEN oxidation. Thus, in addition to COX and LOX enzymes, PLA 2 enzyme levels may confer an additional risk in pancreatic and other cancers by providing a steady concentration of AA.
Materials and methods

Materials
Reagents were AA (NuChek Prep, Elysian, MN, USA); PLA 2 from porcine pancreas, Tiron, N-mercaptopropionylglycine (Sigma-Aldrich, St Louis, MO, USA); NS-398, PGs, TxB 2 , LTB 4 , 5-HETE, Express EIA PGE 2 , PGD 2 and LTB 4 kits (Cayman Laboratories, Ann Arbor, MI, USA); BW-B70C (Biomol Int., Plymouth Meeting, PA, USA); phosphoinositides (Echelon Research Laboratories, Inc., Salt Lake City, UT, USA); iGENOME SMART pool PTEN siRNA and the non-specific control SMART pool siRNA (Dharmacon, Lafayette, CO, USA). Antibodies recognizing COX-2 (Cayman Laboratories, Ann Arbor, MI, USA); 5-LOX (#10694, BD Biosciences Pharmingen, San Diego, CA, USA); Akt (#9271), phospho-(S473)Akt(#9271), K/R-x-K/R-x-x-S/ T(PO 4 ) epitopes (#9614), phospho-(S9)GSK3b (#9336), Phospho-(S241)PDKI (#3061), phospho-(S319)FoxO1 (#2486), PTEN (#9552) (Cell Signaling Technologies) and phospho-(S722)FAK (#07-825) (Upstate, Charlottesville, VA, USA).
Effect of AA on Akt phosphorylation and signaling Cells (B1 Â 10 6 ) serum-starved overnight were treated with 0-60 mM AA for 0.5 h, or with 60 mM AA for 0-2 h (vehicle ¼ ethanol (EtOH)). Cells were also treated with combinations of 10 mM NS-398, 10 mM BW-B70C, 1 mM Tiron, or 1 mM MPG 0.5 h before 60 mM AA. PGE 2 , PGD 2 and LTB 4 secreted from cells into the culture media were quantified by immunoassay. In some experiments, cells were treated for 0.5 h directly with 10 mM of various PGs, TxB 2 , 5-15-hydroxyeicosatetraenoic acid (HETE) or LTB 4 . Lysates from treated cell (15 mg protein) were fractionated on sodium dodecyl sulfate (SDS)-10% polyacrylamide gel electrophoresis (PAGE) under reducing or non-reducing conditions as specified. Proteins were transferred to polyvinylidene fluoride (PVDF) membranes for immunoblot analysis of Akt, phospho-(S473)Akt and other proteins in the Akt kinase signaling pathway.
Detection of oxidized PTEN by alkylation with biotinconjugated maleimide Serum-starved cells were treated for 10 min with 0-60 mM AA and oxidized PTEN was alkylated with biotin-maleimide as described (Kwon et al., 2004) . Briefly, treated cells were washed, frozen, transferred to vacuum and incubated for 1 h at 251 with 1 ml of oxygen-free extraction buffer (50 mM sodium phosphate, pH 7.0/1 mM ethylenediaminetetraacetic acid (EDTA)/10 mM NEM/10 mM iodoacetic acid/1% Triton X-100/5 mM NaF/50 mg/ml leupeptin/50 mg/ml aprotinin). The cell lysate was mixed in SDS to a final concentration of 1% for 2 h at 251 in the dark. Proteins were precipitated in 10% (v/v) trichloroacetic acid for 1 h. The protein precipitate was washed twice with acetone, solubilized and reduced by incubation for 0.5 h at 501C in 0.1 ml of oxygen-free reducing buffer (50 mM Hepes-NaOH, pH 7.7/1 mM EDTA/2% SDS/4 mM DTT). The reduced proteins were biotinylated by incubation for 0.5 h at 501C with 0.9 ml of 50 mM sodium phosphate (pH 7.0), 1 mM EDTA, and 1 mM biotin that had been conjugated to polyethylene oxide-maleimide. Proteins were precipitated in 10% v/v trichloroacetic acid 1 h. The precipitate was solubilized in 0.3 ml of 50 mM Hepes-NaOH (pH 7.7), 1 mM EDTA and 2% SDS. The sample was then diluted with 0.3 ml of the same solution without SDS. A portion of 15 mg of protein was used for Western blot analysis; 200 mg protein was added to 100 ml immobilized neutravidin with phosphate-buffered saline (PBS)/ 0.1% tween at a final volume of 1 ml. Samples were rotated overnight at 41C. Beads were centrifuged and washed two times with PBS/0.1% tween. Loading buffer (50 ml) with 5% bmercaptoethanol was added to the beads, boiled for 10 m to release biotinylated proteins, and 20 ml loaded on a SDS-PAGE. The membrane was probed with an anti-PTEN antibody to detect total PTEN and oxidized PTEN.
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